Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
The green list will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security
Triple receptor agonist: GLP-1 + GIP + Glucagon Latest Phase 3 Highlights (23 July 2026) TRIUMPH-2 22.6% mean weight loss in adults with obesity and cardiovascular disease TRIUMPH-3 20.8% mean weight loss in adults with obesity and type 2 diabetes ~1.6% HbA1c reduction Next milestone Eli Lilly plans to submit its first FDA application for Retatrutide in Q1 2027
LAST DAY TO GRAB THIS
Phase 3 figures point to a 23.7% mean weight loss at its highest dose over 68 weeks, with some trial participants experiencing as much as 28.7% reduction
Thomas, J., Paulet, M
US$ 23.35
US$ 28.74
US$ 24.25
US$ 28.78
US$ 28.01
US$ 25.97
US$ 24.60
US$ 26.33
US$ 24.38
US$ 29.09
US$ 25.55
US$ 21.14
